Young Teresa L. 4
4 · Seres Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Seres (MCRB) EVP Teresa Young Sells 75 Shares to Cover Taxes
What Happened
Teresa L. Young, EVP & Chief Commercial & Strategy Officer of Seres Therapeutics (MCRB), had 231 restricted stock units convert/settle into common shares on February 15, 2026. To cover taxes tied to the vesting, 75 of those shares were sold in the open market at $8.47 per share for total proceeds of ~$635. Additionally, 231 shares were reported as converted/settled (the filing records 133 and 98-share dispositions at $0, reflecting shares withheld/settled with no cash proceeds).
Key Details
- Transaction date: February 15, 2026; Form 4 filed February 18, 2026 (no late filing indicated).
- Open-market sale: 75 shares at $8.47 each; proceeds reported $635.
- Conversion/settlement (derivative conversion): 231 shares converted/settled; 133 and 98 shares reported as disposed at $0 (reflecting shares withheld/settled).
- Shares owned after the transactions: Not specified in this Form 4 filing.
- Notable footnotes:
- F1: Each restricted stock unit (RSU) converts to one share.
- F2: The sale was executed under a Rule 10b5-1 plan (adopted Mar 5, 2023) solely to cover taxes on RSU vesting.
- F3/F4: RSUs vest on a schedule (25% on prior Feb 15 dates, remainder in 12 equal quarterly installments); RSUs have no expiration.
Context
This activity stems from RSU vesting and routine tax-covering actions rather than an open-market investment decision. The conversion of RSUs to shares followed by a small sale and withholding is common for executives to satisfy tax obligations and does not necessarily indicate a change in insider sentiment.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-15+231→ 8,632 total - Sale
Common Stock
[F2]2026-02-15$8.47/sh−75$635→ 8,557 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-02-15−133→ 531 total→ Common Stock (133 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F4]2026-02-15−98→ 780 total→ Common Stock (98 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.